Under our immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize the following AnaptysBio-generated antibody product candidates:
Anti-PD-1 Monospecific Antagonist Antibody (TSR-042): Registration program initiated for metastatic microsatellite instability high (MSI-H) endometrial cancer in Q2 2017;
Anti-TIM-3 Monospecific Antagonist Antibody (TSR-022): Phase 1 clinical trial ongoing, expect initiation of a combination trial with anti-PD-1 in mid-2017;
Anti-LAG-3 Monospecific Antagonist Antibody (TSR-033): U.S. FDA IND cleared, expect initiation of Phase 1 study in mid-2017, and
Anti-PD-1/LAG-3 Bispecific Antagonist Antibody: lead candidate identified, IND-enabling studies on-going.
To access scientific publications on this topic, please click here.